Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3200882 in Patients With Solid Tumors
NCT02937272Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2016
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of ly3200882 in solid tumor (8 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants Who Experienced Dose-Limiting Toxicities at 28 days and Overall Response Rate up to 12 months. Started Nov 2016; status: active, not recruiting.
02
Drugs
ly3200882
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02937272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02937272.